Diabetes Metab J.  2023 Nov;47(6):879-881. 10.4093/dmj.2023.0328.

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)

• Lee DY

• KMID: 2548164
• DOI: http://doi.org/10.4093/dmj.2023.0328

Reference

1. Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022; 21:74.

2. Wong YK, Tse HF. Circulating biomarkers for cardiovascular disease risk prediction in patients with cardiovascular disease. Front Cardiovasc Med. 2021; 8:713191.

3. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215–33.

4. Kaur A, Mackin ST, Schlosser K, Wong FL, Elharram M, Delles C, et al. Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease. Cardiovasc Res. 2020; 116:1113–24.

5. Kraczkowska W, Stachowiak L, Plawski A, Jagodzinski PP. Circulating miRNA as potential biomarkers for diabetes mellitus type 2: should we focus on searching for sex differences? J Appl Genet. 2022; 63:293–303.

6. Pordzik J, Jakubik D, Jarosz-Popek J, Wicik Z, Eyileten C, De Rosa S, et al. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review. Cardiovasc Diabetol. 2019; 18:113.

7. Chandrasekera D, Katare R. Exosomal microRNAs in diabetic heart disease. Cardiovasc Diabetol. 2022; 21:122.

8. Shen NN, Wang JL, Fu YP. The microRNA expression profiling in heart failure: a systematic review and meta-analysis. Front Cardiovasc Med. 2022; 9:856358.

9. Abdallah HY, Hassan R, Fareed A, Abdelgawad M, Mostafa SA, Mohammed EA. Identification of a circulating microRNAs biomarker panel for non-invasive diagnosis of coronary artery disease: case-control study. BMC Cardiovasc Disord. 2022; 22:286.

10. Scherbak NN, Kruse R, Nystrom T, Jendle J. Glimepiride compared to liraglutide increases plasma levels of miR-206, miR-182-5p, and miR-766-3p in type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab J. 2023; 47:668–81.